A little of both really. While no one it's been administered to has died, it's not been administered to many people, and it has been administered without contro

A little of both really. While no one it's been administered to has died, it's not been administered to many people, and it has been administered without control. Which isn't shocking; that's the first phase of human testing, just see if it seems to actually help, and not create issues itself. They're setting up for tests with a control group next. https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-updated-positive-results-phase-1b-study-covi https://investors.sorrentotherapeutics.com/news-releases/new... It could indeed fizzle like Remdesivir. Just, yeah, the data, while promising, is so small it tells us nothing. Hence why the clinical trial process.